Docoh
Loading...

MIRM Mirum Pharmaceuticals

News

From Benzinga Pro
Mirum Pharma Reports Sale Of Its Rare Pediatric Disease Priority Review Voucher For $110M
17 Nov 21
News, Asset Sales
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver disease, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”)
Mirum Pharmaceuticals Q3 EPS $(1.55) Beats $(1.73) Estimate
15 Nov 21
Earnings, News
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of $(1.73) by 10.4 percent. This is a 80.23 percent decrease over losses of $(0.86) per share
Mirum Pharmaceuticals Says Six-Year Natural History Comparison With Co's LIVMARLI (maralixibat) Demonstrates Event-Free Survival And Transplant-Free Survival In Patients With Alagille Syndrome
15 Nov 21
News, FDA
- Results demonstrate statistically significant improvement in six-year event-free survival (p<0.0001) and transplant-free survival (p<0.0001) - Study presented by Global Alagille Alliance (GALA) at The
Earnings Scheduled For November 15, 2021
15 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Mirum Pharmaceuticals Says New LIVMARLI Data To Be Showcased At AASLD The Liver Meeting 2021 On Nov. 12-15
1 Nov 21
News, FDA, Events
- LIVMARLI (maralixibat) late-breaker oral presentation on a six-year event-free survival analysis in Alagille syndrome compared to a natural history cohort; selected for Best of the Liver Meeting - Second
Mirum Pharmaceuticals Highlights Data Published In The Lancet From Co's ICONIC Pivotal Study Of Maralixibat Treatment In Alagille Syndrome
1 Nov 21
News, FDA
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver disease, today announced that The Lancet has published four-year data highlighting the safety and efficacy of maralixibat in patients
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $64
30 Sep 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $51 to $64.
Expert Ratings For Mirum Pharmaceuticals
30 Sep 21
Analyst Ratings
Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings within the last quarter:
10 Biggest Price Target Changes For Thursday
30 Sep 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Jefferies raised Perrigo Company plc (NYSE: PRGO) price target from $45 to $63. Perrigo shares jumped 13.3% to $49.27 in pre-market trading.
Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $69
30 Sep 21
News, Price Target, Analyst Ratings
Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price target from $51 to $69.
SVB Leerink Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $41
30 Sep 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $32 to $41.
FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma
29 Sep 21
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Sep 21
Movers
Gainers
Mirum Pharmaceuticals Says U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
29 Sep 21
Biotech, News, FDA, General
Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep 21
Biotech, M&A, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28)
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
21 Sep 21
Biotech, News, Health Care, Contracts, Small Cap, General
What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals
20 Sep 21
Analyst Ratings
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings:
JP Morgan Initiates Coverage On Mirum Pharmaceuticals with Overweight Rating, Announces Price Target of $30
20 Sep 21
News, Price Target, Initiation, Analyst Ratings
JP Morgan analyst Jessica Fye initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight rating and announces Price Target of $30.
Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Lowers Price Target to $51
14 Sep 21
News, Price Target, Analyst Ratings
Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and lowers the price target from $52 to $51.

Press releases

From Benzinga Pro
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
22 Nov 21
Press Releases
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will participate in the following upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference November 30,
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
17 Nov 21
Press Releases
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver disease, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for $110
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
15 Nov 21
Press Releases
- U.S. commercial launch underway following U.S. FDA approval of LIVMARLI™ (maralixibat) oral solution - Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural
Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
15 Nov 21
Press Releases
- Results demonstrate statistically significant improvement in six-year event-free survival (p<0.0001) and transplant-free survival (p<0.0001) - Study presented by Global Alagille Alliance (GALA) at The Liver
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
8 Nov 21
Press Releases
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the company will report financial results for the quarter ended September 30, 2021 on Monday, November 15, 2021. That same day, Mirum will host a conference
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
1 Nov 21
Press Releases
- LIVMARLI (maralixibat) late-breaker oral presentation on a six-year event-free survival analysis in Alagille syndrome compared to a natural history cohort; selected for Best of the Liver Meeting - Second late-breaker
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
1 Nov 21
Press Releases
- Maralixibat data demonstrate four-year durable and clinically meaningful improvements across multiple cholestasis parameters including pruritus. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
29 Sep 21
Press Releases
Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
13 Sep 21
Press Releases
- Marketing Authorization Application for treatment of cholestatic disease in Alagille syndrome submitted. - Natural history analysis shows significant improvement in event-free survival and transplant-free
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Sep 21
Press Releases
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on September 10, 2021, the Compensation Committee of Mirum's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 87,500
Mirum Pharmaceuticals to Participate in September Investor Conferences
2 Sep 21
Press Releases
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will participate in five investor conferences taking place virtually throughout the month of September. Citi 16th Annual BioPharma Virtual